Related Experiment Video
Updated: Oct 12, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Biomarkers for Treatment Response in Advanced Prostate Cancer
Samia Asif1, Benjamin A Teply1
1Department of Internal Medicine, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198-6840, USA.
Abstract:
Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies-specifically, the sequencing of therapies-is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers.
Insights
Selecting the best sequence of treatments for metastatic prostate cancer is challenging. Biomarkers can help guide therapy choices to improve patient outcomes and avoid ineffective treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Metastatic prostate cancer has multiple treatment options.
- Optimal sequencing of these therapies remains undefined.
- Personalized treatment selection is crucial for improved outcomes.
Purpose of the Study:
- To review established and emerging biomarkers for advanced prostate cancer therapy selection.
- To guide optimal treatment sequencing for improved clinical outcomes.
Main Methods:
- Literature review of prognostic and predictive biomarkers.
- Analysis of biomarkers including tumor molecular sequencing, ctDNA, CTCs, AR characteristics, and PSMA expression.
Main Results:
- Established biomarkers aid in selecting effective therapies.
- Emerging biomarkers show promise for refining treatment decisions.
- Biomarker-guided selection can optimize treatment sequencing.
Conclusions:
- Biomarkers are essential for personalized treatment of metastatic prostate cancer.
- Utilizing predictive biomarkers can enhance therapeutic efficacy and minimize toxicity.
- Further research into emerging biomarkers will refine treatment strategies.
More Related Videos
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018